You are here
Overcoming barriers in progressive multiple sclerosis research
Timothy Coetzee, Paola Zaratin, Trevis L Gleason
The Lancet Neurology, Volume 14, Issue 2, February 2015, Pages 132–133
The past two decades have seen a profound change in the treatment of multiple sclerosis. With recent regulatory approvals, 12 disease-modifying treatments are available in many countries for relapsing-remitting multiple sclerosis (RRMS) and there is a robust pipeline of experimental treatments at various stages of clinical development. Such progress should be a cause for celebration; however, much still needs to be done to make available a similar range of treatments to people living with progressive forms of multiple sclerosis.